People with acute and chronic conditions are supported in their self-treatment by the digital therapy management of Ypsomed and S3 Conncted Health.

Press Releases Ypsomed Group

Burgdorf – Ypsomed (SIX: YPSN) will expand its offering of digital health solutions together with S3 Connected Health in the future. S3 Connected Health, headquartered in Dublin, Ireland is a specialist digital health partner for life science companies. The new offering will allow Ypsomed’s biopharma customers to quickly launch therapy-specific digital patient solutions. People with acute and chronic diseases can thus be supported fully in their therapy management and the outcome of their treatment can be enhanced.

Topics:
Innovation & Digital Health

Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) continues its growth trend and achieved consolidated sales of CHF 497.5 million in the 2022/23 financial year (previous year: CHF 464.8 million). Adjusted for the effect of the divestment of DiaExpert, continuing business demonstrated growth of 16%, or approximately 19% currency adjusted. The reported growth in turnover corresponds to a growth of 7% compared to the previous year. At constant exchange rates compared to the previous year, this would have represented an increase of around 10%. With this growth, the company has significantly increased both its operating profit (EBIT) from CHF 28.6 million to CHF 60.6 million as well as more than doubled its net profits to CHF 51.3 million (previous year CHF 23.1 million). Ypsomed confirms the outlook for the 2023/24 financial year.

Press Releases Ypsomed Group

Burgdorf – Ypsomed (SIX: YPSN) is building a new production hall in Schwerin and creating 60 new jobs in the process. The company held the groundbreaking ceremony last Friday thus signaling the start of the construction for the 3300 square meters of additional production space, plus a further 1600 square meters for warehouse capacity and logistics. Digging work is scheduled to begin in June. The plant is expected to be operational following a construction phase of one year. The expansion will allow Ypsomed's site in Schwerin to produce more than 250 million infusion sets, pens and autoinjectors per year going forward.

Topics:
Access & Expansion

Press Releases Ypsomed Group

Burgdorf – On 25 April 2023, the groundbreaking ceremony for Ypsomed's (SIX: YPSN) new production facility took place in the Changzhou National Hi-tech District. In order to be able to efficiently serve the rapidly growing Chinese market for injection systems, Ypsomed is investing over CHF 35 million in the new manufacturing plant in a first phase. Production is expected to commence in the second half of 2024.

Topics:
Access & Expansion

Dr. Nicolas Meyer succeeds Dr. Beat Maurer on the Executive Board.

Press Releases Ypsomed Group

Burgdorf – Ypsomed announces a change in its Executive Board. After more than thirty years with Ypsomed and formerly Disetronic, Dr Beat Maurer will retire as Chief Legal Officer (CLO) on 31 March 2023. He will be succeeded by Dr Nicolas Meyer, who will take up the position as CLO at Ypsomed on 01 May 2023.